{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:21:15Z","timestamp":1783131675530,"version":"3.54.6"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>This case series reported a group of patients with Guillain\u2013Barr\u00e9 syndrome (GBS) and their plasma cytokine changes before and after immunotherapy. We aimed to understand GBS's pathogenesis and pathophysiology through observing the interval differences of the representative cytokines, which were the thymus and activation regulated chemokine (TARC) for T-cell chemotaxis, CD40 ligand (CD40L) for cosimulation of B and T cells, activated complement component C5\/C5a, and brain-derived neurotrophic factor (BDNF) for survival and regenerative responses to nerve injuries. The fluorescence magnetic bead-based multiplexing immunoassay simultaneously quantified the five cytokines in a single sample. From June 2018 to December 2019, we enrolled five GBS patients who had completed before\u2013after blood cytokine measurements. One patient was diagnosed with paraneoplastic GBS and excluded from the following cytokine analysis. The BDNF level decreased consistently in all the patients and made it a potential biomarker for the acute stage of GBS. Interval changes of the other four cytokines were relatively inconsistent and possibly related to interindividual differences in the immune response to GBS triggers, types of GBS variants, and classes of antiganglioside antibodies. In summary, utilizing the multiplexing immunoassay helps in understanding the complex immune mechanisms of GBS and the variation of immune responses in GBS subtypes; this method is feasible for identifying potential biomarkers of GBS.<\/jats:p>","DOI":"10.3389\/fneur.2021.720794","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T07:59:02Z","timestamp":1630742342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Plasma Biomarkers Reflect Immune Mechanisms of Guillain\u2013Barr\u00e9 Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Chia-Lun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hao","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yi","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chieh","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Chieh","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41423-020-0388-9","article-title":"Physiology of gangliosides and the role of antiganglioside antibodies in human diseases","volume":"17","author":"Cutillo","year":"2020","journal-title":"Cell Mol Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1172\/JCI6837","article-title":"Monoclonal antibodies raised against Guillain-Barr\u00e9 syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations","volume":"104","author":"Goodyear","year":"1999","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/brain\/awq119","article-title":"Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice","volume":"133","author":"McGonigal","year":"2010","journal-title":"Brain."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1523\/JNEUROSCI.3829-10.2011","article-title":"Anti-ganglioside antibody-mediated activation of RhoA induces inhibition of neurite outgrowth","volume":"31","author":"Zhang","year":"2011","journal-title":"J Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.expneurol.2011.12.010","article-title":"Motor nerve terminal destruction and regeneration following anti-ganglioside antibody and complement-mediated injury: an in and ex vivo imaging study in the mouse","volume":"233","author":"Rupp","year":"2012","journal-title":"Exp Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/jnnp.2006.087940","article-title":"Anti-ganglioside complex antibodies in Miller Fisher syndrome","volume":"77","author":"Kaida","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jneuroim.2006.09.013","article-title":"Anti-ganglioside complex antibodies associated with severe disability in GBS","volume":"182","author":"Kaida","year":"2007","journal-title":"J Neuroimmunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"564098","DOI":"10.1155\/2015\/564098","article-title":"Biomarkers of Guillain-Barre syndrome: some recent progress, more still to be explored","volume":"2015","author":"Wang","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/mus.21239","article-title":"CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barre syndrome","volume":"40","author":"Petzold","year":"2009","journal-title":"Muscle Nerve."},{"key":"B10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamaneurol.2016.4480","article-title":"Association of albumin levels with outcome in intravenous immunoglobulin-treated guillain-barre syndrome","volume":"74","author":"Fokkink","year":"2017","journal-title":"JAMA Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-020-01737-0","article-title":"Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barre syndrome","volume":"17","author":"Altmann","year":"2020","journal-title":"J Neuroinflammation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10875-007-9104-0","article-title":"Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus","volume":"27","author":"Chun","year":"2007","journal-title":"J Clin Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mus.25162","article-title":"B-cell-activating factor is elevated in serum of patients with myasthenia gravis","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle Nerve."},{"key":"B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jneuroim.2013.01.001","article-title":"Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action?","volume":"256","author":"Bick","year":"2013","journal-title":"J Neuroimmunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jneuroim.2014.06.007","article-title":"IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"274","author":"Ritter","year":"2014","journal-title":"J Neuroimmunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fnins.2019.00717","article-title":"Peripheral blood and cerebrospinal fluid cytokine levels in Guillain Barre syndrome: a systematic review and meta-analysis","volume":"13","author":"Sun","year":"2019","journal-title":"Front Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1346-8138.12440","article-title":"Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis","volume":"41","author":"Kataoka","year":"2014","journal-title":"J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s12035-018-1283-6","article-title":"Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation","volume":"56","author":"Lima Giacobbo","year":"2019","journal-title":"Mol Neurobiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cyto.b.20021","article-title":"Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers","volume":"61","author":"Khan","year":"2004","journal-title":"Cytometry B Clin Cytom."},{"key":"B24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clim.2003.11.017","article-title":"Cytometric bead array: a multiplexed assay platform with applications in various areas of biology","volume":"110","author":"Morgan","year":"2004","journal-title":"Clin Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barre syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1212\/WNL.43.10.1911","article-title":"Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barr\u00e9 syndrome: clinical and immunohistochemical studies","volume":"43","author":"Chiba","year":"1993","journal-title":"Neurology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1468-1331.2000.00096.x","article-title":"Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barre syndrome: a pilot study","volume":"7","author":"Bensa","year":"2000","journal-title":"Eur J Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/brain\/awg207","article-title":"Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome","volume":"126","author":"Wanschitz","year":"2003","journal-title":"Brain."},{"key":"B29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","article-title":"Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers","volume":"27","author":"Susuki","year":"2007","journal-title":"J Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-5728(96)00133-6","article-title":"Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barr\u00e9 syndrome, myasthenia gravis and dermatomyositis","volume":"71","author":"Basta","year":"1996","journal-title":"J Neuroimmunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1523\/JNEUROSCI.4926-14.2015","article-title":"Anti-ganglioside antibodies induce nodal and axonal injury via fcgamma receptor-mediated inflammation","volume":"35","author":"He","year":"2015","journal-title":"J Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.51","article-title":"TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome","volume":"68","author":"Nyati","year":"2011","journal-title":"Arch Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"740947","DOI":"10.1155\/2014\/740947","article-title":"Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barre syndrome and downregulated by IVIg treatments","volume":"2014","author":"Li","year":"2014","journal-title":"Mediators Inflamm."},{"key":"B37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jneuroim.2007.09.034","article-title":"Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barr\u00e9 syndrome","volume":"192","author":"Chi","year":"2007","journal-title":"J Neuroimmunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jneuroim.2006.12.002","article-title":"Reduced circulating CD4+CD25+ cell populations in Guillain-Barr\u00e9 syndrome","volume":"183","author":"Pritchard","year":"2007","journal-title":"J Neuroimmunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000489919","article-title":"Therapeutic Effect of CD4+CD25+ regulatory T cells amplified in vitro on experimental autoimmune neuritis in rats","volume":"47","author":"Wang","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0165-5728(94)90032-9","article-title":"T lymphocyte subset abnormalities in peripheral blood from patients with the Guillain-Barre syndrome","volume":"53","author":"Dahle","year":"1994","journal-title":"J Neuroimmunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cytogfr.2013.05.005","article-title":"Th1\/Th2\/Th17\/Treg cytokines in Guillain-Barre syndrome and experimental autoimmune neuritis","volume":"24","author":"Zhang","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12883-014-0202-3","article-title":"Changes in lymphocyte subsets in patients with Guillain-Barre syndrome treated with immunoglobulin","volume":"14","author":"Hou","year":"2014","journal-title":"BMC Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and co-inhibitory pathways in autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity."},{"key":"B44","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41573-020-0081-9","article-title":"Targeting co-stimulatory molecules in autoimmune disease","volume":"19","author":"Edner","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.03.019","article-title":"Increased plasmacytoid dendritic cells in Guillain-Barre syndrome","volume":"283","author":"Wang","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/NEN.0000000000000069","article-title":"Costimulatory molecule CD40 is essential for myelin protein 0 peptide 106-125-induced experimental autoimmune neuritis in mice","volume":"73","author":"Brunn","year":"2014","journal-title":"J Neuropathol Exp Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.nbd.2006.11.010","article-title":"B cells play a cooperative role via CD40L-CD40 interaction in T cell-mediated experimental autoimmune neuritis in Lewis rats","volume":"25","author":"Zhu","year":"2007","journal-title":"Neurobiol Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/jnnp.69.3.362","article-title":"Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies","volume":"69","author":"Kiefer","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1212\/01.wnl.0000250240.99311.9d","article-title":"Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies","volume":"68","author":"Hu","year":"2007","journal-title":"Neurology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/mus.23829","article-title":"The role of chemokines in Guillain-Barre syndrome","volume":"48","author":"Chiang","year":"2013","journal-title":"Muscle Nerve."},{"key":"B51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0165-5728(02)00393-4","article-title":"Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barre syndrome and experimental autoimmune neuritis","volume":"134","author":"Orlikowski","year":"2003","journal-title":"J Neuroimmunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2990.2010.01092.x","article-title":"Selective expression and cellular localization of pro-inflammatory chemokine ligand\/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain-Barre syndrome","volume":"36","author":"Xia","year":"2010","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e90463","DOI":"10.1371\/journal.pone.0090463","article-title":"CCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barre syndrome","volume":"9","author":"Yuan","year":"2014","journal-title":"PLoS One."},{"key":"B54","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.nbd.2004.04.007","article-title":"CCR5 deficiency does not prevent P0 peptide 180-199 immunized mice from experimental autoimmune neuritis","volume":"16","author":"Duan","year":"2004","journal-title":"Neurobiol Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/brain\/awf070","article-title":"Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10","volume":"125","author":"Kieseier","year":"2002","journal-title":"Brain."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3390\/ijms18112306","article-title":"The C-C chemokines CCL17 and CCL22 and their receptor CCR4 in CNS autoimmunity","volume":"18","author":"Scheu","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2017.01.004","article-title":"Memory B cells in Guillain-Barre syndrome","volume":"305","author":"Wang","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1086\/513799","article-title":"Mechanisms of action of anti-GM1 and anti-GQ1b ganglioside antibodies in Guillain-Barre syndrome","volume":"176","author":"Willison","year":"1997","journal-title":"J Infect Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2183\/pjab.88.299","article-title":"Guillain-Barre syndrome and anti-ganglioside antibodies: a clinician-scientist's journey","volume":"88","author":"Yuki","year":"2012","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/glycob\/cwp027","article-title":"Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders\u2013a review","volume":"19","author":"Kaida","year":"2009","journal-title":"Glycobiology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.neuropharm.2013.05.043","article-title":"Pre-and postsynaptic twists in BDNF secretion and action in synaptic plasticity","volume":"76","author":"Edelmann","year":"2014","journal-title":"Neuropharmacology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fncel.2014.00430","article-title":"Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity","volume":"8","author":"Calabrese","year":"2014","journal-title":"Front Cell Neurosci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/jnr.20432","article-title":"The secreted brain-derived neurotrophic factor precursor pro-BDNF binds to TrkB and p75NTR but not to TrkA or TrkC","volume":"80","author":"Fayard","year":"2005","journal-title":"J Neurosci Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/FOC.2009.26.2.E3","article-title":"The role of neurotrophic factors in nerve regeneration","volume":"26","author":"Gordon","year":"2009","journal-title":"Neurosurg Focus."},{"key":"B65","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0006-8993(97)00048-6","article-title":"Expression of mRNA for brain-derived neurotrophic factor in the dorsal root ganglion following peripheral inflammation","volume":"749","author":"Cho","year":"1997","journal-title":"Brain Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1083\/jcb.119.1.45","article-title":"Enhanced synthesis of brain-derived neurotrophic factor in the lesioned peripheral nerve: different mechanisms are responsible for the regulation of BDNF and NGF mRNA","volume":"119","author":"Meyer","year":"1992","journal-title":"J Cell Biol."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0419-17.2018","article-title":"Measuring and validating the levels of brain-derived neurotrophic factor in human serum","volume":"5","author":"Naegelin","year":"2018","journal-title":"eNeuro."},{"key":"B68","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1160\/TH06-03-0173","article-title":"Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)- blood levels in Alzheimer's disease","volume":"96","author":"Laske","year":"2006","journal-title":"Thromb Haemost."},{"key":"B69","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1017\/S1461145710001008","article-title":"Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients","volume":"14","author":"Laske","year":"2011","journal-title":"Int J Neuropsychopharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pnpbp.2018.07.010","article-title":"Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis","volume":"88","author":"Jiang","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B71","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ajmg.b.30501","article-title":"Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients","author":"Ciammola","year":"2007","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1017\/S1461145708009309","article-title":"A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression","volume":"11","author":"Brunoni","year":"2008","journal-title":"Int J Neuropsychopharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/jnr.22276","article-title":"Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients","volume":"88","author":"Patanella","year":"2010","journal-title":"J Neurosci Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1177\/1352458510375706","article-title":"Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis","volume":"16","author":"Yoshimura","year":"2010","journal-title":"Mult Scler."},{"key":"B75","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrn3505","article-title":"BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases","volume":"14","author":"Lu","year":"2013","journal-title":"Nat Rev Neurosci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1093\/brain\/awq179","article-title":"Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis","volume":"133","author":"Linker","year":"2010","journal-title":"Brain."},{"key":"B77","doi-asserted-by":"publisher","first-page":"CD008630","DOI":"10.1002\/14651858.CD008630.pub5","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome","volume":"1","author":"Doets","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"CD001798","DOI":"10.1002\/14651858.CD001798.pub3","article-title":"Plasma exchange for Guillain-Barre syndrome","volume":"2","author":"Chevret","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1526-0968.2002.00382.x","article-title":"Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barre syndrome","volume":"6","author":"Lyu","year":"2002","journal-title":"Ther Apher."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur J Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1526-0968.2002.00464.x","article-title":"Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients","volume":"6","author":"Nakae","year":"2002","journal-title":"Ther Apher."},{"key":"B83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ajh.20342","article-title":"Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura","volume":"79","author":"Shariatmadar","year":"2005","journal-title":"Am J Hematol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"CD002063","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barre syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/jnnp.57.9.1118","article-title":"Tumour necrosis factor-alpha and other cytokines in Guillain-Barr\u00e9 syndrome","volume":"57","author":"Exley","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1212\/WNL.52.9.1833","article-title":"I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome","volume":"52","author":"Sharief","year":"1999","journal-title":"Neurology."},{"key":"B87","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jneuroim.2010.09.015","article-title":"Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies","volume":"231","author":"Lehmann","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-all-rounders tackling the versatile players of the immune system","volume":"10","author":"Strehl","year":"2019","journal-title":"Front Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1002\/1521-4141(2000)30:8<2344::AID-IMMU2344>3.0.CO;2-7","article-title":"Glucocorticoids drive human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4, IL-5 and IL-13 production","volume":"30","author":"Richards","year":"2000","journal-title":"Eur J Immunol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.720794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T07:59:07Z","timestamp":1630742347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.720794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":91,"alternative-id":["10.3389\/fneur.2021.720794"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.720794","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"article-number":"720794"}}